2022 CME Statement

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education (ACCME) through the joint providership of the American Gastroenterological Association (AGA) Institute and the Crohn’s & Colitis Foundation. The AGA Institute is accredited by the ACCME to provide continuing medical education for physicians.

The AGA Institute designates this live activity for a maximum of 13.5 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

In accordance with the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education, all faculty and planning partners must disclose all their financial relationship(s) with ineligible companies held within the past 24 months . The AGA Institute implements a mechanism to identify and resolve all conflicts of interest prior to delivering the educational activity to learners.


The AGA MOC module will be available for attendees by February 14th.. A link will be sent to all attendees.

Learning Objectives

At the close of the 2022 Congress, participants will be able to:

  • List emerging therapies in IBD.
  • Describe the role of nutrition and dietary management in IBD.
  • Identify the strengths and limitations of IBD therapeutic options based on the latest evidence and best practices.
  • Employ the best practices supporting IBD management in the COVID-19 era.
  • Explain the latest evidence supporting personalized medicine in IBD.
  • Distinguish how technology advances are changing the landscape of clinical practice.
  • Incorporate knowledge gained toward a multi-disciplinary dialogue and coordinated IBD management.
  • Describe the role of behavioral and lifestyle therapies as factors in the management of IBD.